{"abstracts-retrieval-response": {
    "item": {
        "ait:process-info": {
            "ait:status": {
                "@state": "update",
                "@type": "core",
                "@stage": "S300"
            },
            "ait:date-delivered": {
                "@day": "07",
                "@timestamp": "2021-06-07T02:18:10.000010-04:00",
                "@year": "2021",
                "@month": "06"
            },
            "ait:date-sort": {
                "@day": "01",
                "@year": "2021",
                "@month": "02"
            }
        },
        "xocs:meta": {"xocs:funding-list": {
            "@pui-match": "primary",
            "@has-funding-info": "1",
            "xocs:funding": [
                {
                    "xocs:funding-agency-acronym": "NHLBI",
                    "xocs:funding-agency": "National Heart, Lung, and Blood Institute",
                    "xocs:funding-id": "U01HL143365",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100000050",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001"
                },
                {
                    "xocs:funding-agency-matched-string": "BMS",
                    "xocs:funding-agency-acronym": "BMS",
                    "xocs:funding-agency": "Bristol-Myers Squibb",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100002491",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "Pfizer",
                    "xocs:funding-agency": "Pfizer",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100004319",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "Bayer",
                    "xocs:funding-agency-acronym": "BF",
                    "xocs:funding-agency": "Bayer Fund",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100015340",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "Leo Pharma",
                    "xocs:funding-agency": "LEO Pharma Research Foundation",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/501100008271",
                    "xocs:funding-agency-country": "http://sws.geonames.org/2623032/"
                }
            ],
            "xocs:funding-addon-generated-timestamp": "2023-03-02T00:25:56.072657Z",
            "xocs:funding-text": "Drs. Chiasakul and Patell have no disclosures. Dr. Maraveyas reports educational grant from BMS and Bayer; Lecturing Honoraria from BMS, Pfizer, Bayer, Leo Pharma, and Daichii Sankyo; and Advisory Board Honoraria from Pfizer, Bayer, Leo Pharma. Dr. Carrier reports research Funding from BMS, Leo Pharma, and Pfizer; Honoraria from Bayer, BMS, Leo Pharam, Sanofi, Pfizer, and Servier. Dr. Zwicker reports research funding from Incyte and Quercegen; Consultancy with Sanofi, CSL, and Parexel; and Honoraria/advisory boards: Pfizer/BMS, Portola, and Dova.",
            "xocs:funding-addon-type": "http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/aggregated-refined"
        }},
        "bibrecord": {
            "head": {
                "author-group": [
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60022183",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "Division of Hematology"},
                                {"$": "Department of Medicine"},
                                {"$": "Faculty of Medicine"},
                                {"$": "Thai Red Cross Society"},
                                {"$": "Chulalongkorn University and King Chulalongkorn Memorial Hospital"}
                            ],
                            "affiliation-id": [
                                {
                                    "@afid": "60022183",
                                    "@dptid": "100291259"
                                },
                                {"@afid": "60031780"},
                                {"@afid": "60028190"}
                            ],
                            "@affiliation-instance-id": "2007491024-a0651ab2d9c493ec2ebf3c453379bfcf",
                            "ce:source-text": "Division of Hematology, Department of Medicine, Faculty of Medicine, Thai Red Cross Society, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand",
                            "@dptid": "100291259"
                        },
                        "author": [{
                            "ce:given-name": "Thita",
                            "preferred-name": {
                                "ce:given-name": "Thita",
                                "ce:initials": "T.",
                                "ce:surname": "Chiasakul",
                                "ce:indexed-name": "Chiasakul T."
                            },
                            "@author-instance-id": "2007491024-0f098e1b5033aaac60782b3df6711f99",
                            "@seq": "1",
                            "ce:initials": "T.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Chiasakul",
                            "@auid": "56938997200",
                            "@orcid": "0000-0002-0443-1751",
                            "ce:indexed-name": "Chiasakul T."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60002746",
                            "@country": "usa",
                            "city": "Boston",
                            "organization": [
                                {"$": "Division of Hemostasis and Thrombosis"},
                                {"$": "Beth Israel Deaconess Medical Center"},
                                {"$": "Harvard Medical School"}
                            ],
                            "affiliation-id": [
                                {
                                    "@afid": "60002746",
                                    "@dptid": "103189050"
                                },
                                {"@afid": "60030058"}
                            ],
                            "state": "MA",
                            "@affiliation-instance-id": "2007491024-4e7177fbc824aa4f43eabda488df26cc",
                            "ce:source-text": "Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA",
                            "@dptid": "103189050"
                        },
                        "author": [
                            {
                                "ce:given-name": "Thita",
                                "preferred-name": {
                                    "ce:given-name": "Thita",
                                    "ce:initials": "T.",
                                    "ce:surname": "Chiasakul",
                                    "ce:indexed-name": "Chiasakul T."
                                },
                                "@author-instance-id": "2007491024-0f098e1b5033aaac60782b3df6711f99",
                                "@seq": "1",
                                "ce:initials": "T.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Chiasakul",
                                "@auid": "56938997200",
                                "ce:indexed-name": "Chiasakul T."
                            },
                            {
                                "ce:given-name": "Rushad",
                                "preferred-name": {
                                    "ce:given-name": "Rushad",
                                    "ce:initials": "R.",
                                    "ce:surname": "Patell",
                                    "ce:indexed-name": "Patell R."
                                },
                                "@author-instance-id": "2007491024-bc7dd1f2998b440c10042c6efb7a0918",
                                "@seq": "2",
                                "ce:initials": "R.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Patell",
                                "@auid": "54682133800",
                                "@orcid": "0000-0002-8426-3398",
                                "ce:indexed-name": "Patell R."
                            },
                            {
                                "ce:given-name": "Jeffrey I.",
                                "preferred-name": {
                                    "ce:given-name": "Jeffrey I.",
                                    "ce:initials": "J.I.",
                                    "ce:surname": "Zwicker",
                                    "ce:indexed-name": "Zwicker J.I."
                                },
                                "@author-instance-id": "2007491024-0b9505ac9479c902339dac1c4f99b098",
                                "@seq": "5",
                                "ce:initials": "J.I.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Zwicker",
                                "@auid": "7003326377",
                                "@orcid": "0000-0001-5810-6893",
                                "ce:indexed-name": "Zwicker J.I."
                            }
                        ]
                    },
                    {
                        "affiliation": {
                            "country": "United Kingdom",
                            "@afid": "60107756",
                            "@country": "gbr",
                            "city": "Hull",
                            "organization": {"$": "Hull York Medical School"},
                            "affiliation-id": {"@afid": "60107756"},
                            "@affiliation-instance-id": "2007491024-7fe51cf9f0bb908c056c751ca97cb17c",
                            "ce:source-text": "Hull York Medical School, Hull, UK"
                        },
                        "author": [
                            {
                                "ce:given-name": "Anthony",
                                "preferred-name": {
                                    "ce:given-name": "Anthony",
                                    "ce:initials": "A.",
                                    "ce:surname": "Maraveyas",
                                    "ce:indexed-name": "Maraveyas A."
                                },
                                "@author-instance-id": "2007491024-a12f0d4ad11f177cc1b85f7b2f20a140",
                                "@seq": "3",
                                "ce:initials": "A.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Maraveyas",
                                "@auid": "6701792215",
                                "@orcid": "0000-0003-4176-5176",
                                "ce:indexed-name": "Maraveyas A."
                            },
                            {
                                "ce:given-name": "Marc",
                                "preferred-name": {
                                    "ce:given-name": "Marc",
                                    "ce:initials": "M.",
                                    "ce:surname": "Carrier",
                                    "ce:indexed-name": "Carrier M."
                                },
                                "@author-instance-id": "2007491024-1c966ca9a281e73778f6d7ecd8b9a5db",
                                "@seq": "4",
                                "ce:initials": "M.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Carrier",
                                "@auid": "57196834193",
                                "ce:indexed-name": "Carrier M."
                            }
                        ]
                    },
                    {
                        "affiliation": {
                            "country": "Canada",
                            "@afid": "60002173",
                            "@country": "can",
                            "city": "Ottawa",
                            "organization": [
                                {"$": "Department of Medicine"},
                                {"$": "Ottawa Hospital Research Institute"},
                                {"$": "University of Ottawa"}
                            ],
                            "affiliation-id": [
                                {"@afid": "60002173"},
                                {"@afid": "60028897"},
                                {"@afid": "60085927"}
                            ],
                            "@affiliation-instance-id": "2007491024-4e8006c8071b6cee3a00ca6c8c64fbd9",
                            "ce:source-text": "Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada"
                        },
                        "author": [{
                            "ce:given-name": "Marc",
                            "preferred-name": {
                                "ce:given-name": "Marc",
                                "ce:initials": "M.",
                                "ce:surname": "Carrier",
                                "ce:indexed-name": "Carrier M."
                            },
                            "@author-instance-id": "2007491024-1c966ca9a281e73778f6d7ecd8b9a5db",
                            "@seq": "4",
                            "ce:initials": "M.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Carrier",
                            "@auid": "57196834193",
                            "ce:indexed-name": "Carrier M."
                        }]
                    }
                ],
                "citation-title": "Discordant reporting of VTE in pancreatic cancer: A systematic review and meta-analysis of thromboprophylaxis versus chemotherapeutic trials",
                "abstracts": "Â© 2020 International Society on Thrombosis and HaemostasisBackground: Despite the frequency of venous thromboembolism (VTE) in pancreatic cancer, it is inconsistently reported as an adverse event in clinical trials. We hypothesized that reported rates of VTE in pancreatic cancer clinical trials are influenced by the objectives of the trial, with higher rates reported in thromboprophylaxis compared with chemotherapeutic trials. We performed a systematic review and meta-analysis of randomized, controlled trials (RCT) in pancreatic cancer to quantify differences in reported rates of VTE in thromboprophylaxis and chemotherapeutic trials. Methods: We systematically searched MEDLINE, EMBASE, and Clinicaltrials.gov. Eligible thromboprophylaxis RCTs were required to report rates of thrombosis in non-anticoagulant pancreatic cancer cohorts. Eligible chemotherapy studies were RCTs evaluating chemotherapy regimens in advanced pancreatic cancer and reported thrombosis as adverse events. Pooled event rates of VTE and arterial thrombosis were calculated using a random-effects model. Results: The pooled VTE rate in 13 chemotherapy studies (5694 patients) was 5.9% (95% confidence interval [CI], 3.9-9.0%) compared with 16.5% (95% CI, 11.7%-23.3%; P <.001) in 9 thromboprophylaxis studies (631 patients). The pooled symptomatic VTE rate from chemotherapy studies was 5.4% (95% CI, 3.5%-8.3%), which was significantly lower than the pooled rate from thromboprophylaxis studies of 10.5% (95% CI, 7.3%-14.9%; P =.02). Conclusion: The VTE incidence reported in chemotherapy RCTs in pancreatic cancer is significantly lower than reported in thromboprophylaxis studies. This finding highlights the underrecognition of VTE in chemotherapeutic trials and emphasizes the need to standardize approaches towards monitoring and reporting of VTE in clinical trials.",
                "correspondence": {
                    "affiliation": {
                        "country": "United States",
                        "@country": "usa",
                        "city": "Boston",
                        "organization": [
                            {"$": "Division of Hemostasis and Thrombosis"},
                            {"$": "Beth Israel Deaconess Medical Center"},
                            {"$": "Harvard Medical School"}
                        ],
                        "state": "MA",
                        "ce:source-text": "Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA"
                    },
                    "person": {
                        "ce:given-name": "Jeffrey I.",
                        "ce:initials": "J.I.",
                        "ce:surname": "Zwicker",
                        "ce:indexed-name": "Zwicker J.I."
                    }
                },
                "citation-info": {
                    "author-keywords": {"author-keyword": [
                        {
                            "$": "anticoagulants",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "pancreatic neoplasms",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "thromboembolism",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "thrombosis",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "venous thromboembolism",
                            "@xml:lang": "eng",
                            "@original": "y"
                        }
                    ]},
                    "citation-type": {"@code": "ar"},
                    "citation-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    },
                    "abstract-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    }
                },
                "source": {
                    "website": {"ce:e-address": {
                        "$": "http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1538-7836",
                        "@type": "email"
                    }},
                    "translated-sourcetitle": {
                        "$": "Journal of Thrombosis and Haemostasis",
                        "@xml:lang": "eng"
                    },
                    "volisspag": {
                        "voliss": {
                            "@volume": "19",
                            "@issue": "2"
                        },
                        "pagerange": {
                            "@first": "489",
                            "@last": "501"
                        }
                    },
                    "@type": "j",
                    "sourcetitle": "Journal of Thrombosis and Haemostasis",
                    "publicationdate": {
                        "month": "02",
                        "year": "2021",
                        "date-text": "February 2021",
                        "day": "01"
                    },
                    "codencode": "JTHOA",
                    "sourcetitle-abbrev": "J. Thromb. Haemost.",
                    "@country": "gbr",
                    "issn": [
                        {
                            "$": "15387836",
                            "@type": "electronic"
                        },
                        {
                            "$": "15387933",
                            "@type": "print"
                        }
                    ],
                    "publicationyear": {"@first": "2021"},
                    "publisher": {"publishername": "Blackwell Publishing Ltd"},
                    "@srcid": "26000"
                },
                "enhancement": {
                    "classificationgroup": {"classifications": [
                        {
                            "@type": "EMCLASS",
                            "classification": [
                                {
                                    "classification-code": "16",
                                    "classification-description": "Cancer"
                                },
                                {
                                    "classification-code": "25",
                                    "classification-description": "Hematology"
                                },
                                {
                                    "classification-code": "37",
                                    "classification-description": "Drug Literature Index"
                                },
                                {
                                    "classification-code": "38",
                                    "classification-description": "Adverse Reactions Titles"
                                },
                                {
                                    "classification-code": "48",
                                    "classification-description": "Gastroenterology"
                                }
                            ]
                        },
                        {
                            "@type": "ASJC",
                            "classification": "2720"
                        },
                        {
                            "@type": "SUBJABBR",
                            "classification": "MEDI"
                        }
                    ]},
                    "tradenamegroup": {"tradenames": {
                        "trademanuitem": {"tradename": "gv 1001"},
                        "@type": "TNM"
                    }},
                    "chemicalgroup": {"chemicals": [
                        {
                            "@source": "esbd",
                            "chemical": [
                                {
                                    "cas-registry-number": [
                                        {"$": "845771-78-0"},
                                        {"$": "862111-32-8"}
                                    ],
                                    "chemical-name": "aflibercept"
                                },
                                {
                                    "cas-registry-number": "319460-85-0",
                                    "chemical-name": "axitinib"
                                },
                                {
                                    "cas-registry-number": [
                                        {"$": "216974-75-3"},
                                        {"$": "1438851-35-4"}
                                    ],
                                    "chemical-name": "bevacizumab"
                                },
                                {
                                    "cas-registry-number": "154361-50-9",
                                    "chemical-name": "capecitabine"
                                },
                                {
                                    "cas-registry-number": "918633-87-1",
                                    "chemical-name": "evofosfamide"
                                },
                                {
                                    "cas-registry-number": "51-21-8",
                                    "chemical-name": "fluorouracil"
                                },
                                {
                                    "cas-registry-number": [
                                        {"$": "1492-18-8"},
                                        {"$": "51057-63-7"}
                                    ],
                                    "chemical-name": "folinate calcium"
                                },
                                {
                                    "cas-registry-number": "103882-84-4",
                                    "chemical-name": "gemcitabine"
                                },
                                {
                                    "cas-registry-number": "132682-98-5",
                                    "chemical-name": "glufosfamide"
                                },
                                {
                                    "cas-registry-number": "957472-14-9",
                                    "chemical-name": "golnerminogene pradenovec"
                                },
                                {
                                    "cas-registry-number": [
                                        {"$": "100286-90-6"},
                                        {"$": "97682-44-5"}
                                    ],
                                    "chemical-name": "irinotecan"
                                },
                                {
                                    "cas-registry-number": "790299-79-5",
                                    "chemical-name": "masitinib"
                                },
                                {
                                    "cas-registry-number": "61825-94-3",
                                    "chemical-name": "oxaliplatin"
                                },
                                {
                                    "cas-registry-number": "33069-62-4",
                                    "chemical-name": "paclitaxel"
                                },
                                {
                                    "cas-registry-number": [
                                        {"$": "1092939-17-7"},
                                        {"$": "941678-49-5"}
                                    ],
                                    "chemical-name": "ruxolitinib"
                                },
                                {
                                    "cas-registry-number": "284461-73-0",
                                    "chemical-name": "sorafenib"
                                },
                                {
                                    "cas-registry-number": "915019-08-8",
                                    "chemical-name": "tertomotide"
                                },
                                {
                                    "cas-registry-number": [
                                        {"$": "192185-72-1"},
                                        {"$": "192185-68-5"}
                                    ],
                                    "chemical-name": "tipifarnib"
                                }
                            ]
                        },
                        {
                            "@source": "nlm",
                            "chemical": [
                                {"chemical-name": "Anticoagulants"},
                                {"chemical-name": "Heparin, Low-Molecular-Weight"}
                            ]
                        }
                    ]}
                },
                "grantlist": {
                    "@complete": "y",
                    "grant": {
                        "grant-id": "U01HL143365",
                        "grant-acronym": "NHLBI",
                        "grant-agency": {
                            "@iso-code": "usa",
                            "$": "National Heart, Lung, and Blood Institute"
                        },
                        "grant-agency-id": "100000050"
                    }
                }
            },
            "item-info": {
                "copyright": {
                    "$": "Copyright 2021 Elsevier B.V., All rights reserved.",
                    "@type": "Elsevier"
                },
                "external-source": "MEDLINE",
                "dbcollection": [
                    {"$": "EMBASE"},
                    {"$": "MEDL"},
                    {"$": "REAXYSCAR"},
                    {"$": "SCOPUS"},
                    {"$": "Scopusbase"}
                ],
                "history": {"date-created": {
                    "@day": "04",
                    "@timestamp": "BST 08:45:14",
                    "@year": "2021",
                    "@month": "06"
                }},
                "itemidlist": {
                    "itemid": [
                        {
                            "$": "2007491024",
                            "@idtype": "PUI"
                        },
                        {
                            "$": "633399554",
                            "@idtype": "associatedPUI"
                        },
                        {
                            "$": "929995625",
                            "@idtype": "CAR-ID"
                        },
                        {
                            "$": "20201067740",
                            "@idtype": "EMBASE"
                        },
                        {
                            "$": "33174368",
                            "@idtype": "MEDL"
                        },
                        {
                            "$": "20202884458",
                            "@idtype": "REAXYSCAR"
                        },
                        {
                            "$": "20204236494",
                            "@idtype": "SCOPUS"
                        },
                        {
                            "$": "20200288219450",
                            "@idtype": "TPA-ID"
                        },
                        {
                            "$": "85097018464",
                            "@idtype": "SCP"
                        },
                        {
                            "$": "85097018464",
                            "@idtype": "SGR"
                        },
                        {
                            "$": "633399554",
                            "@idtype": "PUIsecondary"
                        },
                        {
                            "$": "78277399",
                            "@idtype": "OSIN"
                        }
                    ],
                    "ce:doi": "10.1111/jth.15175"
                }
            },
            "tail": {"bibliography": {
                "@refcount": "46",
                "reference": [
                    {
                        "ref-fulltext": "Lyman GH, Culakova E, Poniewierski MS, Kuderer NM. Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. Thromb Res. 2018;164(Suppl 1):S112-S118. https://doi.org/10.1016/j.thromres.2018.01.028",
                        "@id": "1",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1016/j.thromres.2018.01.028",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0001",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85046023712",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "164"},
                                "pagerange": {
                                    "@first": "S112",
                                    "@last": "S118"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "G.H.",
                                    "@_fa": "true",
                                    "ce:surname": "Lyman",
                                    "ce:indexed-name": "Lyman G.H."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "E.",
                                    "@_fa": "true",
                                    "ce:surname": "Culakova",
                                    "ce:indexed-name": "Culakova E."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "M.S.",
                                    "@_fa": "true",
                                    "ce:surname": "Poniewierski",
                                    "ce:indexed-name": "Poniewierski M.S."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "N.M.",
                                    "@_fa": "true",
                                    "ce:surname": "Kuderer",
                                    "ce:indexed-name": "Kuderer N.M."
                                }
                            ]},
                            "ref-sourcetitle": "Thromb Res"
                        },
                        "ce:source-text": "Lyman GH, Culakova E, Poniewierski MS, Kuderer NM. Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. Thromb Res. 2018;164(Suppl 1):S112-S118. https://doi.org/10.1016/j.thromres.2018.01.028"
                    },
                    {
                        "ref-fulltext": "Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013;119:648-655. https://doi.org/10.1002/cncr.27772",
                        "@id": "2",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1002/cncr.27772",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0002",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84872922620",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "119"},
                                "pagerange": {
                                    "@first": "648",
                                    "@last": "655"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "A.A.",
                                    "@_fa": "true",
                                    "ce:surname": "Khorana",
                                    "ce:indexed-name": "Khorana A.A."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "M.",
                                    "@_fa": "true",
                                    "ce:surname": "Dalal",
                                    "ce:indexed-name": "Dalal M."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "J.",
                                    "@_fa": "true",
                                    "ce:surname": "Lin",
                                    "ce:indexed-name": "Lin J."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "G.C.",
                                    "@_fa": "true",
                                    "ce:surname": "Connolly",
                                    "ce:indexed-name": "Connolly G.C."
                                }
                            ]},
                            "ref-sourcetitle": "Cancer"
                        },
                        "ce:source-text": "Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013;119:648-655. https://doi.org/10.1002/cncr.27772"
                    },
                    {
                        "ref-fulltext": "Menapace LA, Peterson DR, Berry A, Sousou T, Khorana AA. Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost. 2011;106:371-378. https://doi.org/10.1160/TH10-12-0789",
                        "@id": "3",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2011"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1160/TH10-12-0789",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0003",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "79961071836",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "106"},
                                "pagerange": {
                                    "@first": "371",
                                    "@last": "378"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "L.A.",
                                    "@_fa": "true",
                                    "ce:surname": "Menapace",
                                    "ce:indexed-name": "Menapace L.A."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "D.R.",
                                    "@_fa": "true",
                                    "ce:surname": "Peterson",
                                    "ce:indexed-name": "Peterson D.R."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Berry",
                                    "ce:indexed-name": "Berry A."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "T.",
                                    "@_fa": "true",
                                    "ce:surname": "Sousou",
                                    "ce:indexed-name": "Sousou T."
                                },
                                {
                                    "@seq": "5",
                                    "ce:initials": "A.A.",
                                    "@_fa": "true",
                                    "ce:surname": "Khorana",
                                    "ce:indexed-name": "Khorana A.A."
                                }
                            ]},
                            "ref-sourcetitle": "Thromb Haemost"
                        },
                        "ce:source-text": "Menapace LA, Peterson DR, Berry A, Sousou T, Khorana AA. Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost. 2011;106:371-378. https://doi.org/10.1160/TH10-12-0789"
                    },
                    {
                        "ref-fulltext": "Frere C, Bournet B, Gourgou S, et al., Consortium B. Incidence of venous thromboembolism in patients with newly diagnosed pancreatic cancer and factors associated with outcomes. Gastroenterology. 2020;158:1346-1358 e4. https://doi.org/10.1053/j.gastro.2019.12.009",
                        "@id": "4",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1053/j.gastro.2019.12.009",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Incidence of venous thromboembolism in patients with newly diagnosed pancreatic cancer and factors associated with outcomes"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0004",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85081953571",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "158"},
                                "pagerange": {
                                    "@first": "1346",
                                    "@last": "1358"
                                }
                            },
                            "ref-text": "e4",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Frere",
                                        "ce:indexed-name": "Frere C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Bournet",
                                        "ce:indexed-name": "Bournet B."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Gourgou",
                                        "ce:indexed-name": "Gourgou S."
                                    }
                                ],
                                "collaboration": {
                                    "@seq": "1",
                                    "ce:text": "Consortium B",
                                    "ce:indexed-name": "Consortium B"
                                },
                                "et-al": null
                            },
                            "ref-sourcetitle": "Gastroenterology"
                        },
                        "ce:source-text": "Frere C, Bournet B, Gourgou S, et al., Consortium B. Incidence of venous thromboembolism in patients with newly diagnosed pancreatic cancer and factors associated with outcomes. Gastroenterology. 2020;158:1346-1358 e4. https://doi.org/10.1053/j.gastro.2019.12.009"
                    },
                    {
                        "ref-fulltext": "Farge D, Bournet B, Conroy T, et al. Primary thromboprophylaxis in pancreatic cancer patients. Why clinical practice guidelines should be implemented. Cancers (Basel). 2020;12:1-23. https://doi.org/10.3390/cancers12030618",
                        "@id": "5",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.3390/cancers12030618",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Primary thromboprophylaxis in pancreatic cancer patients. Why clinical practice guidelines should be implemented"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0005",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85081259436",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "12"},
                                "pagerange": {
                                    "@first": "1",
                                    "@last": "23"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Farge",
                                        "ce:indexed-name": "Farge D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Bournet",
                                        "ce:indexed-name": "Bournet B."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Conroy",
                                        "ce:indexed-name": "Conroy T."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancers (Basel)"
                        },
                        "ce:source-text": "Farge D, Bournet B, Conroy T, et al. Primary thromboprophylaxis in pancreatic cancer patients. Why clinical practice guidelines should be implemented. Cancers (Basel). 2020;12:1-23. https://doi.org/10.3390/cancers12030618"
                    },
                    {
                        "ref-fulltext": "Donnellan E, Khorana AA. Cancer and venous thromboembolic disease: a review. Oncologist. 2017;22:199-207. https://doi.org/10.1634/theoncologist.2016-0214",
                        "@id": "6",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1634/theoncologist.2016-0214",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Cancer and venous thromboembolic disease: a review"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0006",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85014528241",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "22"},
                                "pagerange": {
                                    "@first": "199",
                                    "@last": "207"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "E.",
                                    "@_fa": "true",
                                    "ce:surname": "Donnellan",
                                    "ce:indexed-name": "Donnellan E."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "A.A.",
                                    "@_fa": "true",
                                    "ce:surname": "Khorana",
                                    "ce:indexed-name": "Khorana A.A."
                                }
                            ]},
                            "ref-sourcetitle": "Oncologist"
                        },
                        "ce:source-text": "Donnellan E, Khorana AA. Cancer and venous thromboembolic disease: a review. Oncologist. 2017;22:199-207. https://doi.org/10.1634/theoncologist.2016-0214"
                    },
                    {
                        "ref-fulltext": "Carrier M, Khorana AA, Zwicker JI, et al. Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis. J Thromb Haemost. 2012;10:2599-2601. https://doi.org/10.1111/jth.12028",
                        "@id": "7",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2012"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1111/jth.12028",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0007",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84871079890",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "10"},
                                "pagerange": {
                                    "@first": "2599",
                                    "@last": "2601"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Carrier",
                                        "ce:indexed-name": "Carrier M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Khorana",
                                        "ce:indexed-name": "Khorana A.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.I.",
                                        "@_fa": "true",
                                        "ce:surname": "Zwicker",
                                        "ce:indexed-name": "Zwicker J.I."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Thromb Haemost"
                        },
                        "ce:source-text": "Carrier M, Khorana AA, Zwicker JI, et al. Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis. J Thromb Haemost. 2012;10:2599-2601. https://doi.org/10.1111/jth.12028"
                    },
                    {
                        "ref-fulltext": "Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380:711-719. https://doi.org/10.1056/NEJMoa1814468",
                        "@id": "8",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1056/NEJMoa1814468",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Apixaban to prevent venous thromboembolism in patients with cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0008",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85058848099",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "380"},
                                "pagerange": {
                                    "@first": "711",
                                    "@last": "719"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Carrier",
                                        "ce:indexed-name": "Carrier M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Abou-Nassar",
                                        "ce:indexed-name": "Abou-Nassar K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Mallick",
                                        "ce:indexed-name": "Mallick R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380:711-719. https://doi.org/10.1056/NEJMoa1814468"
                    },
                    {
                        "ref-fulltext": "Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380:720-728. https://doi.org/10.1056/NEJMoa1814630",
                        "@id": "9",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1056/NEJMoa1814630",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0009",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85061961689",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "380"},
                                "pagerange": {
                                    "@first": "720",
                                    "@last": "728"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Khorana",
                                        "ce:indexed-name": "Khorana A.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "G.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Soff",
                                        "ce:indexed-name": "Soff G.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.K.",
                                        "@_fa": "true",
                                        "ce:surname": "Kakkar",
                                        "ce:indexed-name": "Kakkar A.K."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380:720-728. https://doi.org/10.1056/NEJMoa1814630"
                    },
                    {
                        "ref-fulltext": "Maraveyas A, Waters J, Roy R, et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer. 2012;48:1283-1292. https://doi.org/10.1016/j.ejca.2011.10.017",
                        "@id": "10",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2012"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1016/j.ejca.2011.10.017",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0010",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84861334022",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "48"},
                                "pagerange": {
                                    "@first": "1283",
                                    "@last": "1292"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Maraveyas",
                                        "ce:indexed-name": "Maraveyas A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Waters",
                                        "ce:indexed-name": "Waters J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Roy",
                                        "ce:indexed-name": "Roy R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Eur J Cancer"
                        },
                        "ce:source-text": "Maraveyas A, Waters J, Roy R, et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer. 2012;48:1283-1292. https://doi.org/10.1016/j.ejca.2011.10.017"
                    },
                    {
                        "ref-fulltext": "Pelzer U, Opitz B, Deutschinoff G, et al. Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. J Clin Oncol. 2015;33:2028-2034. https://doi.org/10.1200/JCO.2014.55.1481",
                        "@id": "11",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1200/JCO.2014.55.1481",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0011",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84937622422",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "33"},
                                "pagerange": {
                                    "@first": "2028",
                                    "@last": "2034"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "U.",
                                        "@_fa": "true",
                                        "ce:surname": "Pelzer",
                                        "ce:indexed-name": "Pelzer U."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Opitz",
                                        "ce:indexed-name": "Opitz B."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Deutschinoff",
                                        "ce:indexed-name": "Deutschinoff G."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Pelzer U, Opitz B, Deutschinoff G, et al. Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. J Clin Oncol. 2015;33:2028-2034. https://doi.org/10.1200/JCO.2014.55.1481"
                    },
                    {
                        "ref-fulltext": "Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002;20:3270-3275. https://doi.org/10.1200/jco.2002.11.149",
                        "@id": "12",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2002"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1200/jco.2002.11.149",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0012",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "0036682041",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "20"},
                                "pagerange": {
                                    "@first": "3270",
                                    "@last": "3275"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "J.D.",
                                    "@_fa": "true",
                                    "ce:surname": "Berlin",
                                    "ce:indexed-name": "Berlin J.D."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "P.",
                                    "@_fa": "true",
                                    "ce:surname": "Catalano",
                                    "ce:indexed-name": "Catalano P."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "J.P.",
                                    "@_fa": "true",
                                    "ce:surname": "Thomas",
                                    "ce:indexed-name": "Thomas J.P."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "J.W.",
                                    "@_fa": "true",
                                    "ce:surname": "Kugler",
                                    "ce:indexed-name": "Kugler J.W."
                                },
                                {
                                    "@seq": "5",
                                    "ce:initials": "D.G.",
                                    "@_fa": "true",
                                    "ce:surname": "Haller",
                                    "ce:indexed-name": "Haller D.G."
                                },
                                {
                                    "@seq": "6",
                                    "ce:initials": "A.B.",
                                    "@_fa": "true",
                                    "ce:surname": "Benson",
                                    "ce:suffix": "3rd",
                                    "ce:indexed-name": "Benson A.B."
                                }
                            ]},
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002;20:3270-3275. https://doi.org/10.1200/jco.2002.11.149"
                    },
                    {
                        "ref-fulltext": "Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-1825. https://doi.org/10.1056/NEJMoa1011923",
                        "@id": "13",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2011"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1056/NEJMoa1011923",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0013",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "79955921754",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "364"},
                                "pagerange": {
                                    "@first": "1817",
                                    "@last": "1825"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Conroy",
                                        "ce:indexed-name": "Conroy T."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Desseigne",
                                        "ce:indexed-name": "Desseigne F."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Ychou",
                                        "ce:indexed-name": "Ychou M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-1825. https://doi.org/10.1056/NEJMoa1011923"
                    },
                    {
                        "ref-fulltext": "Herman JM, Wild AT, Wang H, et al. Randomized phase iii multi-institutional study of tnferade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. J Clin Oncol. 2013;31:886-894. https://doi.org/10.1200/JCO.2012.44.7516",
                        "@id": "14",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1200/JCO.2012.44.7516",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Randomized phase iii multi-institutional study of tnferade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0014",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84875729716",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "31"},
                                "pagerange": {
                                    "@first": "886",
                                    "@last": "894"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Herman",
                                        "ce:indexed-name": "Herman J.M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.T.",
                                        "@_fa": "true",
                                        "ce:surname": "Wild",
                                        "ce:indexed-name": "Wild A.T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Wang",
                                        "ce:indexed-name": "Wang H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Herman JM, Wild AT, Wang H, et al. Randomized phase iii multi-institutional study of tnferade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. J Clin Oncol. 2013;31:886-894. https://doi.org/10.1200/JCO.2012.44.7516"
                    },
                    {
                        "ref-fulltext": "Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366:601-609. https://doi.org/10.1056/NEJMoa1108898",
                        "@id": "15",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2012"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1056/NEJMoa1108898",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0015",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84857129296",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "366"},
                                "pagerange": {
                                    "@first": "601",
                                    "@last": "609"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Agnelli",
                                        "ce:indexed-name": "Agnelli G."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.J.",
                                        "@_fa": "true",
                                        "ce:surname": "George",
                                        "ce:indexed-name": "George D.J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.K.",
                                        "@_fa": "true",
                                        "ce:surname": "Kakkar",
                                        "ce:indexed-name": "Kakkar A.K."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366:601-609. https://doi.org/10.1056/NEJMoa1108898"
                    },
                    {
                        "ref-fulltext": "Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10:943-949. https://doi.org/10.1016/S1470-2045(09)70232-3",
                        "@id": "16",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2009"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1016/S1470-2045(09)70232-3",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0016",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "70349398317",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "10"},
                                "pagerange": {
                                    "@first": "943",
                                    "@last": "949"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Agnelli",
                                        "ce:indexed-name": "Agnelli G."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Gussoni",
                                        "ce:indexed-name": "Gussoni G."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Bianchini",
                                        "ce:indexed-name": "Bianchini C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10:943-949. https://doi.org/10.1016/S1470-2045(09)70232-3"
                    },
                    {
                        "ref-fulltext": "Zwicker JI, Liebman HA, Bauer KA, et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). Br J Haematol. 2013;160:530-537. https://doi.org/10.1111/bjh.12163",
                        "@id": "17",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1111/bjh.12163",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0017",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84873094723",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "160"},
                                "pagerange": {
                                    "@first": "530",
                                    "@last": "537"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.I.",
                                        "@_fa": "true",
                                        "ce:surname": "Zwicker",
                                        "ce:indexed-name": "Zwicker J.I."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Liebman",
                                        "ce:indexed-name": "Liebman H.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "K.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Bauer",
                                        "ce:indexed-name": "Bauer K.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Br J Haematol"
                        },
                        "ce:source-text": "Zwicker JI, Liebman HA, Bauer KA, et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). Br J Haematol. 2013;160:530-537. https://doi.org/10.1111/bjh.12163"
                    },
                    {
                        "ref-fulltext": "Dronov O, Zemskov S, Zemskova M, Voroniak O. Low molecular heparin in prevention of thromboembolism in out-patients with non-resectable pancreatic cancer. Pancreatology. 2015;15:S88.",
                        "@id": "18",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "Low molecular heparin in prevention of thromboembolism in out-patients with non-resectable pancreatic cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0018",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85097012054",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "15"},
                                "pagerange": {"@first": "S88"}
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "O.",
                                    "@_fa": "true",
                                    "ce:surname": "Dronov",
                                    "ce:indexed-name": "Dronov O."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "S.",
                                    "@_fa": "true",
                                    "ce:surname": "Zemskov",
                                    "ce:indexed-name": "Zemskov S."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "M.",
                                    "@_fa": "true",
                                    "ce:surname": "Zemskova",
                                    "ce:indexed-name": "Zemskova M."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "O.",
                                    "@_fa": "true",
                                    "ce:surname": "Voroniak",
                                    "ce:indexed-name": "Voroniak O."
                                }
                            ]},
                            "ref-sourcetitle": "Pancreatology"
                        },
                        "ce:source-text": "Dronov O, Zemskov S, Zemskova M, Voroniak O. Low molecular heparin in prevention of thromboembolism in out-patients with non-resectable pancreatic cancer. Pancreatology. 2015;15:S88."
                    },
                    {
                        "ref-fulltext": "Vadhan-Raj S, Zhou X, Varadhachary GR, et al. Randomized controlled trial of dalteparin for primary thromboprophylaxis for venous thromboembolism (VTE) in patients with advanced pancreatic cancer (APC): risk factors predictive of VTE. Blood. 2013;122.",
                        "@id": "19",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-title": {"ref-titletext": "Randomized controlled trial of dalteparin for primary thromboprophylaxis for venous thromboembolism (VTE) in patients with advanced pancreatic cancer (APC): risk factors predictive of VTE"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0019",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84899767842",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {"voliss": {"@volume": "122"}},
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Vadhan-Raj",
                                        "ce:indexed-name": "Vadhan-Raj S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "X.",
                                        "@_fa": "true",
                                        "ce:surname": "Zhou",
                                        "ce:indexed-name": "Zhou X."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "G.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Varadhachary",
                                        "ce:indexed-name": "Varadhachary G.R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Vadhan-Raj S, Zhou X, Varadhachary GR, et al. Randomized controlled trial of dalteparin for primary thromboprophylaxis for venous thromboembolism (VTE) in patients with advanced pancreatic cancer (APC): risk factors predictive of VTE. Blood. 2013;122."
                    },
                    {
                        "ref-fulltext": "Wasielewski S. Matrix metalloproteinases: target for new cancer therapies. Med Monatsschr Pharm. 2001;24:2-5.",
                        "@id": "20",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2001"},
                            "ref-title": {"ref-titletext": "Matrix metalloproteinases: target for new cancer therapies"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0020",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "18244432232",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "24"},
                                "pagerange": {
                                    "@first": "2",
                                    "@last": "5"
                                }
                            },
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "S.",
                                "@_fa": "true",
                                "ce:surname": "Wasielewski",
                                "ce:indexed-name": "Wasielewski S."
                            }]},
                            "ref-sourcetitle": "Med Monatsschr Pharm"
                        },
                        "ce:source-text": "Wasielewski S. Matrix metalloproteinases: target for new cancer therapies. Med Monatsschr Pharm. 2001;24:2-5."
                    },
                    {
                        "ref-fulltext": "Ciuleanu TE, Pavlovsky AV, Bodoky G, et al. A randomised phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. Eur J Cancer. 2009;45:1589-1596. https://doi.org/10.1016/j.ejca.2008.12.022",
                        "@id": "21",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2009"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1016/j.ejca.2008.12.022",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "A randomised phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0021",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "67349272693",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "45"},
                                "pagerange": {
                                    "@first": "1589",
                                    "@last": "1596"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "T.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Ciuleanu",
                                        "ce:indexed-name": "Ciuleanu T.E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.V.",
                                        "@_fa": "true",
                                        "ce:surname": "Pavlovsky",
                                        "ce:indexed-name": "Pavlovsky A.V."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Bodoky",
                                        "ce:indexed-name": "Bodoky G."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Eur J Cancer"
                        },
                        "ce:source-text": "Ciuleanu TE, Pavlovsky AV, Bodoky G, et al. A randomised phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. Eur J Cancer. 2009;45:1589-1596. https://doi.org/10.1016/j.ejca.2008.12.022"
                    },
                    {
                        "ref-fulltext": "Deplanque G, Demarchi M, Hebbar M, et al. A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. Annals Oncol. 2015;26:1194-1200. https://doi.org/10.1093/annonc/mdv133",
                        "@id": "22",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1093/annonc/mdv133",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0022",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84938084839",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "26"},
                                "pagerange": {
                                    "@first": "1194",
                                    "@last": "1200"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Deplanque",
                                        "ce:indexed-name": "Deplanque G."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Demarchi",
                                        "ce:indexed-name": "Demarchi M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Hebbar",
                                        "ce:indexed-name": "Hebbar M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Annals Oncol"
                        },
                        "ce:source-text": "Deplanque G, Demarchi M, Hebbar M, et al. A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. Annals Oncol. 2015;26:1194-1200. https://doi.org/10.1093/annonc/mdv133"
                    },
                    {
                        "ref-fulltext": "Gill S, Ko YJ, Cripps C, et al. PANCREOX: a randomized phase III study of fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol. 2016;34:3914-3920. https://doi.org/10.1200/JCO.2016.68.5776",
                        "@id": "23",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1200/JCO.2016.68.5776",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "PANCREOX: a randomized phase III study of fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0023",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84995527140",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "34"},
                                "pagerange": {
                                    "@first": "3914",
                                    "@last": "3920"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Gill",
                                        "ce:indexed-name": "Gill S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Y.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Ko",
                                        "ce:indexed-name": "Ko Y.J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Cripps",
                                        "ce:indexed-name": "Cripps C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Gill S, Ko YJ, Cripps C, et al. PANCREOX: a randomized phase III study of fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol. 2016;34:3914-3920. https://doi.org/10.1200/JCO.2016.68.5776"
                    },
                    {
                        "ref-fulltext": "Goncalves A, Gilabert M, Francois E, et al. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Annals Oncol. 2012;23:2799-2805. https://doi.org/10.1093/annonc/mds135",
                        "@id": "24",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2012"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1093/annonc/mds135",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0024",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84868107516",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "23"},
                                "pagerange": {
                                    "@first": "2799",
                                    "@last": "2805"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Goncalves",
                                        "ce:indexed-name": "Goncalves A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Gilabert",
                                        "ce:indexed-name": "Gilabert M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Francois",
                                        "ce:indexed-name": "Francois E."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Annals Oncol"
                        },
                        "ce:source-text": "Goncalves A, Gilabert M, Francois E, et al. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Annals Oncol. 2012;23:2799-2805. https://doi.org/10.1093/annonc/mds135"
                    },
                    {
                        "ref-fulltext": "Hurwitz H, Van Cutsem E, Bendell J, et al. Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. Invest New Drugs. 2018;36:683-695. https://doi.org/10.1007/s10637-018-0580-2",
                        "@id": "25",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1007/s10637-018-0580-2",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0025",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85045051764",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "36"},
                                "pagerange": {
                                    "@first": "683",
                                    "@last": "695"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Hurwitz",
                                        "ce:indexed-name": "Hurwitz H."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Van Cutsem",
                                        "ce:indexed-name": "Van Cutsem E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Bendell",
                                        "ce:indexed-name": "Bendell J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Invest New Drugs"
                        },
                        "ce:source-text": "Hurwitz H, Van Cutsem E, Bendell J, et al. Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. Invest New Drugs. 2018;36:683-695. https://doi.org/10.1007/s10637-018-0580-2"
                    },
                    {
                        "ref-fulltext": "Kindler HL, Ioka T, Richel DJ, et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol. 2011;12:256-262. https://doi.org/10.1016/S1470-2045(11)70004-3",
                        "@id": "26",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2011"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1016/S1470-2045(11)70004-3",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0026",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "79952036599",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "12"},
                                "pagerange": {
                                    "@first": "256",
                                    "@last": "262"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "H.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Kindler",
                                        "ce:indexed-name": "Kindler H.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Ioka",
                                        "ce:indexed-name": "Ioka T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Richel",
                                        "ce:indexed-name": "Richel D.J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "Kindler HL, Ioka T, Richel DJ, et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol. 2011;12:256-262. https://doi.org/10.1016/S1470-2045(11)70004-3"
                    },
                    {
                        "ref-fulltext": "Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28:3617-3622. https://doi.org/10.1200/JCO.2010.28.1386",
                        "@id": "27",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2010"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1200/JCO.2010.28.1386",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0027",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "77955887676",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "28"},
                                "pagerange": {
                                    "@first": "3617",
                                    "@last": "3622"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "H.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Kindler",
                                        "ce:indexed-name": "Kindler H.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Niedzwiecki",
                                        "ce:indexed-name": "Niedzwiecki D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Hollis",
                                        "ce:indexed-name": "Hollis D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28:3617-3622. https://doi.org/10.1200/JCO.2010.28.1386"
                    },
                    {
                        "ref-fulltext": "Lima CMR, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004;22:3776-3783. https://doi.org/10.1200/JCO.2004.12.082",
                        "@id": "28",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2004"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1200/JCO.2004.12.082",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0028",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "4644327989",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "22"},
                                "pagerange": {
                                    "@first": "3776",
                                    "@last": "3783"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.M.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Lima",
                                        "ce:indexed-name": "Lima C.M.R."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Green",
                                        "ce:indexed-name": "Green M.R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Rotche",
                                        "ce:indexed-name": "Rotche R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Lima CMR, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004;22:3776-3783. https://doi.org/10.1200/JCO.2004.12.082"
                    },
                    {
                        "ref-fulltext": "Middleton G, Silcocks P, Cox T, et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol. 2014;15:829-840. https://doi.org/10.1016/S1470-2045(14)70236-0",
                        "@id": "29",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1016/S1470-2045(14)70236-0",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0029",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84903527674",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "15"},
                                "pagerange": {
                                    "@first": "829",
                                    "@last": "840"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Middleton",
                                        "ce:indexed-name": "Middleton G."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Silcocks",
                                        "ce:indexed-name": "Silcocks P."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Cox",
                                        "ce:indexed-name": "Cox T."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "Middleton G, Silcocks P, Cox T, et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol. 2014;15:829-840. https://doi.org/10.1016/S1470-2045(14)70236-0"
                    },
                    {
                        "ref-fulltext": "Rougier P, Riess H, Manges R, et al. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. Eur J Cancer. 2013;49:2633-2642. https://doi.org/10.1016/j.ejca.2013.04.002",
                        "@id": "30",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1016/j.ejca.2013.04.002",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0030",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84879952361",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "49"},
                                "pagerange": {
                                    "@first": "2633",
                                    "@last": "2642"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Rougier",
                                        "ce:indexed-name": "Rougier P."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Riess",
                                        "ce:indexed-name": "Riess H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Manges",
                                        "ce:indexed-name": "Manges R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Eur J Cancer"
                        },
                        "ce:source-text": "Rougier P, Riess H, Manges R, et al. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. Eur J Cancer. 2013;49:2633-2642. https://doi.org/10.1016/j.ejca.2013.04.002"
                    },
                    {
                        "ref-fulltext": "Van Cutsem E, Van De Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004;22:1430-1438. https://doi.org/10.1200/JCO.2004.10.112",
                        "@id": "31",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2004"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1200/JCO.2004.10.112",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0031",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "2342645506",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "22"},
                                "pagerange": {
                                    "@first": "1430",
                                    "@last": "1438"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Van Cutsem",
                                        "ce:indexed-name": "Van Cutsem E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Van De Velde",
                                        "ce:indexed-name": "Van De Velde H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Karasek",
                                        "ce:indexed-name": "Karasek P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Van Cutsem E, Van De Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004;22:1430-1438. https://doi.org/10.1200/JCO.2004.10.112"
                    },
                    {
                        "ref-fulltext": "Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691-1703. https://doi.org/10.1056/NEJMoa1304369",
                        "@id": "32",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1056/NEJMoa1304369",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0032",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84886741654",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "369"},
                                "pagerange": {
                                    "@first": "1691",
                                    "@last": "1703"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Von Hoff",
                                        "ce:indexed-name": "Von Hoff D.D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Ervin",
                                        "ce:indexed-name": "Ervin T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F.P.",
                                        "@_fa": "true",
                                        "ce:surname": "Arena",
                                        "ce:indexed-name": "Arena F.P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691-1703. https://doi.org/10.1056/NEJMoa1304369"
                    },
                    {
                        "ref-fulltext": "Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387:545-557. https://doi.org/10.1016/S0140-6736(15)00986-1",
                        "@id": "33",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1016/S0140-6736(15)00986-1",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0033",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84959459386",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "387"},
                                "pagerange": {
                                    "@first": "545",
                                    "@last": "557"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Wang-Gillam",
                                        "ce:indexed-name": "Wang-Gillam A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.P.",
                                        "@_fa": "true",
                                        "ce:surname": "Li",
                                        "ce:indexed-name": "Li C.P."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Bodoky",
                                        "ce:indexed-name": "Bodoky G."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet"
                        },
                        "ce:source-text": "Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387:545-557. https://doi.org/10.1016/S0140-6736(15)00986-1"
                    },
                    {
                        "ref-fulltext": "Van Cutsem E, Lenz HJ, Furuse J, et al. MAESTRO: a randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol. 2016;34.",
                        "@id": "34",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "MAESTRO: a randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0034",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85013197769",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {"voliss": {"@volume": "34"}},
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Van Cutsem",
                                        "ce:indexed-name": "Van Cutsem E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Lenz",
                                        "ce:indexed-name": "Lenz H.J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Furuse",
                                        "ce:indexed-name": "Furuse J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Van Cutsem E, Lenz HJ, Furuse J, et al. MAESTRO: a randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol. 2016;34."
                    },
                    {
                        "ref-fulltext": "Loehrer PJ Sr, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29:4105-4112. https://doi.org/10.1200/JCO.2011.34.8904",
                        "@id": "35",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2011"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1200/JCO.2011.34.8904",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0035",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "80755143456",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "29"},
                                "pagerange": {
                                    "@first": "4105",
                                    "@last": "4112"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Loehrer",
                                        "ce:suffix": "Sr.",
                                        "ce:indexed-name": "Loehrer P.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Feng",
                                        "ce:indexed-name": "Feng Y."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Cardenes",
                                        "ce:indexed-name": "Cardenes H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Loehrer PJ Sr, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29:4105-4112. https://doi.org/10.1200/JCO.2011.34.8904"
                    },
                    {
                        "ref-fulltext": "Moore MJ, Goldstein D, Hamm J, et al. National Cancer Institute of Canada Clinical Trials G. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966. https://doi.org/10.1200/JCO.2006.07.9525",
                        "@id": "36",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2007"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1200/JCO.2006.07.9525",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "National Cancer Institute of Canada Clinical Trials G. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0036",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "34249933404",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "25"},
                                "pagerange": {
                                    "@first": "1960",
                                    "@last": "1966"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Moore",
                                        "ce:indexed-name": "Moore M.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Goldstein",
                                        "ce:indexed-name": "Goldstein D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Hamm",
                                        "ce:indexed-name": "Hamm J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Moore MJ, Goldstein D, Hamm J, et al. National Cancer Institute of Canada Clinical Trials G. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966. https://doi.org/10.1200/JCO.2006.07.9525"
                    },
                    {
                        "ref-fulltext": "MandalÃ  M, Moro C, Labianca R, Ferretti G. Erlotinib in pancreatic cancer patients: do we need more information from the NCIC CTG trial? J Clin Oncol. 2007;25:4320-4321. https://doi.org/10.1200/jco.2007.12.8801",
                        "@id": "37",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2007"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1200/jco.2007.12.8801",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Erlotinib in pancreatic cancer patients: do we need more information from the NCIC CTG trial?"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0037",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "34948839916",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "25"},
                                "pagerange": {
                                    "@first": "4320",
                                    "@last": "4321"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "M.",
                                    "@_fa": "true",
                                    "ce:surname": "MandalÃ ",
                                    "ce:indexed-name": "Mandala M."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "C.",
                                    "@_fa": "true",
                                    "ce:surname": "Moro",
                                    "ce:indexed-name": "Moro C."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "R.",
                                    "@_fa": "true",
                                    "ce:surname": "Labianca",
                                    "ce:indexed-name": "Labianca R."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "G.",
                                    "@_fa": "true",
                                    "ce:surname": "Ferretti",
                                    "ce:indexed-name": "Ferretti G."
                                }
                            ]},
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "MandalÃ  M, Moro C, Labianca R, Ferretti G. Erlotinib in pancreatic cancer patients: do we need more information from the NCIC CTG trial? J Clin Oncol. 2007;25:4320-4321. https://doi.org/10.1200/jco.2007.12.8801"
                    },
                    {
                        "ref-fulltext": "Belknap SM, Georgopoulos CH, Lagman J, et al. Reporting of serious adverse events during cancer clinical trials to the institutional review board: an evaluation by the research on adverse drug events and reports (RADAR) project. J Clin Pharmacol. 2013;53:1334-1340. https://doi.org/10.1002/jcph.177",
                        "@id": "38",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1002/jcph.177",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Reporting of serious adverse events during cancer clinical trials to the institutional review board: an evaluation by the research on adverse drug events and reports (RADAR) project"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0038",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84893003677",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "53"},
                                "pagerange": {
                                    "@first": "1334",
                                    "@last": "1340"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Belknap",
                                        "ce:indexed-name": "Belknap S.M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Georgopoulos",
                                        "ce:indexed-name": "Georgopoulos C.H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Lagman",
                                        "ce:indexed-name": "Lagman J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Pharmacol"
                        },
                        "ce:source-text": "Belknap SM, Georgopoulos CH, Lagman J, et al. Reporting of serious adverse events during cancer clinical trials to the institutional review board: an evaluation by the research on adverse drug events and reports (RADAR) project. J Clin Pharmacol. 2013;53:1334-1340. https://doi.org/10.1002/jcph.177"
                    },
                    {
                        "ref-fulltext": "Sivendran S, Galsky MD. Adverse event reporting in oncology clinical trials - lost in translation? Expert Opin Drug Saf. 2016;15:893-896. https://doi.org/10.1080/14740338.2016.1175429",
                        "@id": "39",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1080/14740338.2016.1175429",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Adverse event reporting in oncology clinical trials - lost in translation?"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0039",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84976562676",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "15"},
                                "pagerange": {
                                    "@first": "893",
                                    "@last": "896"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "S.",
                                    "@_fa": "true",
                                    "ce:surname": "Sivendran",
                                    "ce:indexed-name": "Sivendran S."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "M.D.",
                                    "@_fa": "true",
                                    "ce:surname": "Galsky",
                                    "ce:indexed-name": "Galsky M.D."
                                }
                            ]},
                            "ref-sourcetitle": "Expert Opin Drug Saf"
                        },
                        "ce:source-text": "Sivendran S, Galsky MD. Adverse event reporting in oncology clinical trials - lost in translation? Expert Opin Drug Saf. 2016;15:893-896. https://doi.org/10.1080/14740338.2016.1175429"
                    },
                    {
                        "ref-fulltext": "Mandala M, Barni S, Floriani I, et al. Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings. Eur J Cancer. 2009;45:65-73. https://doi.org/10.1016/j.ejca.2008.09.005",
                        "@id": "40",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2009"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1016/j.ejca.2008.09.005",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0040",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "57749097351",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "45"},
                                "pagerange": {
                                    "@first": "65",
                                    "@last": "73"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Mandala",
                                        "ce:indexed-name": "Mandala M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Barni",
                                        "ce:indexed-name": "Barni S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "I.",
                                        "@_fa": "true",
                                        "ce:surname": "Floriani",
                                        "ce:indexed-name": "Floriani I."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Eur J Cancer"
                        },
                        "ce:source-text": "Mandala M, Barni S, Floriani I, et al. Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings. Eur J Cancer. 2009;45:65-73. https://doi.org/10.1016/j.ejca.2008.09.005"
                    },
                    {
                        "ref-fulltext": "Farge D, Frere C, Connors JM, et al. international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;2019(20):e566-e581. https://doi.org/10.1016/s1470-2045(19)30336-5",
                        "@id": "41",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1016/s1470-2045(19)30336-5",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0041",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85072673415",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "2019",
                                    "@issue": "20"
                                },
                                "pagerange": {
                                    "@first": "e566",
                                    "@last": "e581"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Farge",
                                        "ce:indexed-name": "Farge D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Frere",
                                        "ce:indexed-name": "Frere C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Connors",
                                        "ce:indexed-name": "Connors J.M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "Farge D, Frere C, Connors JM, et al. international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;2019(20):e566-e581. https://doi.org/10.1016/s1470-2045(19)30336-5"
                    },
                    {
                        "ref-fulltext": "Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38:496-520. https://doi.org/10.1200/JCO.19.01461",
                        "@id": "42",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1200/JCO.19.01461",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0042",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85079075710",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "38"},
                                "pagerange": {
                                    "@first": "496",
                                    "@last": "520"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Key",
                                        "ce:indexed-name": "Key N.S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Khorana",
                                        "ce:indexed-name": "Khorana A.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Kuderer",
                                        "ce:indexed-name": "Kuderer N.M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38:496-520. https://doi.org/10.1200/JCO.19.01461"
                    },
                    {
                        "ref-fulltext": "National Comprehensive Cancer Network. Cancer-Associated Venous Thromboembolic Disease (version 1.2020). 2020.",
                        "@id": "43",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0043",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85097029927",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "National Comprehensive Cancer Network",
                                "ce:indexed-name": "National Comprehensive Cancer Network"
                            }},
                            "ref-sourcetitle": "Cancer-Associated Venous Thromboembolic Disease (version 1.2020)"
                        },
                        "ce:source-text": "National Comprehensive Cancer Network. Cancer-Associated Venous Thromboembolic Disease (version 1.2020). 2020."
                    },
                    {
                        "ref-fulltext": "Wang TF, Zwicker JI, Ay C, et al. The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2019;17:1772-1778. https://doi.org/10.1111/jth.14564",
                        "@id": "44",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1111/jth.14564",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: guidance from the SSC of the ISTH"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0044",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85072790507",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "17"},
                                "pagerange": {
                                    "@first": "1772",
                                    "@last": "1778"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "T.F.",
                                        "@_fa": "true",
                                        "ce:surname": "Wang",
                                        "ce:indexed-name": "Wang T.F."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.I.",
                                        "@_fa": "true",
                                        "ce:surname": "Zwicker",
                                        "ce:indexed-name": "Zwicker J.I."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Ay",
                                        "ce:indexed-name": "Ay C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Thromb Haemost"
                        },
                        "ce:source-text": "Wang TF, Zwicker JI, Ay C, et al. The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2019;17:1772-1778. https://doi.org/10.1111/jth.14564"
                    },
                    {
                        "ref-fulltext": "Dallos MC, Eisenberger AB, Bates SE. Prevention of venous thromboembolism in pancreatic cancer: breaking down a complex clinical dilemma. Oncologist. 2020;25:132-139. https://doi.org/10.1634/theoncologist.2019-0264",
                        "@id": "45",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1634/theoncologist.2019-0264",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Prevention of venous thromboembolism in pancreatic cancer: breaking down a complex clinical dilemma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0045",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85074414366",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "25"},
                                "pagerange": {
                                    "@first": "132",
                                    "@last": "139"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "M.C.",
                                    "@_fa": "true",
                                    "ce:surname": "Dallos",
                                    "ce:indexed-name": "Dallos M.C."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "A.B.",
                                    "@_fa": "true",
                                    "ce:surname": "Eisenberger",
                                    "ce:indexed-name": "Eisenberger A.B."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "S.E.",
                                    "@_fa": "true",
                                    "ce:surname": "Bates",
                                    "ce:indexed-name": "Bates S.E."
                                }
                            ]},
                            "ref-sourcetitle": "Oncologist"
                        },
                        "ce:source-text": "Dallos MC, Eisenberger AB, Bates SE. Prevention of venous thromboembolism in pancreatic cancer: breaking down a complex clinical dilemma. Oncologist. 2020;25:132-139. https://doi.org/10.1634/theoncologist.2019-0264"
                    },
                    {
                        "ref-fulltext": "Vadhan-Raj S, McNamara MG, Venerito M, et al. Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: results from a pre-specified subgroup analysis of the randomized CASSINI study. Cancer Med. 2020;9:6196-6204. https://doi.org/10.1002/cam4.3269",
                        "@id": "46",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1002/cam4.3269",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: results from a pre-specified subgroup analysis of the randomized CASSINI study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "jth15175-cit-0046",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85087805287",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "9"},
                                "pagerange": {
                                    "@first": "6196",
                                    "@last": "6204"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Vadhan-Raj",
                                        "ce:indexed-name": "Vadhan-Raj S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.G.",
                                        "@_fa": "true",
                                        "ce:surname": "McNamara",
                                        "ce:indexed-name": "McNamara M.G."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Venerito",
                                        "ce:indexed-name": "Venerito M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancer Med"
                        },
                        "ce:source-text": "Vadhan-Raj S, McNamara MG, Venerito M, et al. Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: results from a pre-specified subgroup analysis of the randomized CASSINI study. Cancer Med. 2020;9:6196-6204. https://doi.org/10.1002/cam4.3269"
                    }
                ]
            }}
        }
    },
    "affiliation": [
        {
            "affiliation-city": "Hull",
            "@id": "60107756",
            "affilname": "Hull York Medical School",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60107756",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Boston",
            "@id": "60002746",
            "affilname": "Harvard Medical School",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002746",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Ottawa",
            "@id": "60002173",
            "affilname": "Ottawa Hospital Research Institute",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002173",
            "affiliation-country": "Canada"
        }
    ],
    "coredata": {
        "srctype": "j",
        "eid": "2-s2.0-85097018464",
        "dc:description": "Background: Despite the frequency of venous thromboembolism (VTE) in pancreatic cancer, it is inconsistently reported as an adverse event in clinical trials. We hypothesized that reported rates of VTE in pancreatic cancer clinical trials are influenced by the objectives of the trial, with higher rates reported in thromboprophylaxis compared with chemotherapeutic trials. We performed a systematic review and meta-analysis of randomized, controlled trials (RCT) in pancreatic cancer to quantify differences in reported rates of VTE in thromboprophylaxis and chemotherapeutic trials. Methods: We systematically searched MEDLINE, EMBASE, and Clinicaltrials.gov. Eligible thromboprophylaxis RCTs were required to report rates of thrombosis in non-anticoagulant pancreatic cancer cohorts. Eligible chemotherapy studies were RCTs evaluating chemotherapy regimens in advanced pancreatic cancer and reported thrombosis as adverse events. Pooled event rates of VTE and arterial thrombosis were calculated using a random-effects model. Results: The pooled VTE rate in 13 chemotherapy studies (5694 patients) was 5.9% (95% confidence interval [CI], 3.9-9.0%) compared with 16.5% (95% CI, 11.7%-23.3%; P <.001) in 9 thromboprophylaxis studies (631 patients). The pooled symptomatic VTE rate from chemotherapy studies was 5.4% (95% CI, 3.5%-8.3%), which was significantly lower than the pooled rate from thromboprophylaxis studies of 10.5% (95% CI, 7.3%-14.9%; P =.02). Conclusion: The VTE incidence reported in chemotherapy RCTs in pancreatic cancer is significantly lower than reported in thromboprophylaxis studies. This finding highlights the underrecognition of VTE in chemotherapeutic trials and emphasizes the need to standardize approaches towards monitoring and reporting of VTE in clinical trials.",
        "pubmed-id": "33174368",
        "prism:coverDate": "2021-02-01",
        "prism:aggregationType": "Journal",
        "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/85097018464",
        "dc:creator": {"author": [{
            "ce:given-name": "Thita",
            "preferred-name": {
                "ce:given-name": "Thita",
                "ce:initials": "T.",
                "ce:surname": "Chiasakul",
                "ce:indexed-name": "Chiasakul T."
            },
            "@seq": "1",
            "ce:initials": "T.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60022183",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183"
                },
                {
                    "@id": "60002746",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002746"
                }
            ],
            "ce:surname": "Chiasakul",
            "@auid": "56938997200",
            "author-url": "https://api.elsevier.com/content/author/author_id/56938997200",
            "ce:indexed-name": "Chiasakul T."
        }]},
        "link": [
            {
                "@_fa": "true",
                "@rel": "self",
                "@href": "https://api.elsevier.com/content/abstract/scopus_id/85097018464"
            },
            {
                "@_fa": "true",
                "@rel": "scopus",
                "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85097018464&origin=inward"
            },
            {
                "@_fa": "true",
                "@rel": "scopus-citedby",
                "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85097018464&origin=inward"
            }
        ],
        "source-id": "26000",
        "citedby-count": "11",
        "prism:volume": "19",
        "subtype": "ar",
        "dc:title": "Discordant reporting of VTE in pancreatic cancer: A systematic review and meta-analysis of thromboprophylaxis versus chemotherapeutic trials",
        "openaccess": "1",
        "prism:issn": "15387836 15387933",
        "publishercopyright": "Â© 2020 International Society on Thrombosis and Haemostasis",
        "prism:issueIdentifier": "2",
        "subtypeDescription": "Article",
        "prism:publicationName": "Journal of Thrombosis and Haemostasis",
        "prism:pageRange": "489-501",
        "prism:endingPage": "501",
        "openaccessFlag": "true",
        "prism:doi": "10.1111/jth.15175",
        "prism:startingPage": "489",
        "dc:identifier": "SCOPUS_ID:85097018464",
        "dc:publisher": "Blackwell Publishing Ltd"
    },
    "idxterms": {"mainterm": [
        {
            "$": "Anticoagulants",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Heparin, Low-Molecular-Weight",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Humans",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Pancreatic Neoplasms",
            "@weight": "a",
            "@candidate": "n"
        },
        {
            "$": "Pulmonary Embolism",
            "@weight": "a",
            "@candidate": "n"
        },
        {
            "$": "Venous Thromboembolism",
            "@weight": "a",
            "@candidate": "n"
        }
    ]},
    "language": {"@xml:lang": "eng"},
    "authkeywords": {"author-keyword": [
        {
            "@_fa": "true",
            "$": "anticoagulants"
        },
        {
            "@_fa": "true",
            "$": "pancreatic neoplasms"
        },
        {
            "@_fa": "true",
            "$": "thromboembolism"
        },
        {
            "@_fa": "true",
            "$": "thrombosis"
        },
        {
            "@_fa": "true",
            "$": "venous thromboembolism"
        }
    ]},
    "subject-areas": {"subject-area": [{
        "@_fa": "true",
        "$": "Hematology",
        "@code": "2720",
        "@abbrev": "MEDI"
    }]},
    "authors": {"author": [
        {
            "ce:given-name": "Thita",
            "preferred-name": {
                "ce:given-name": "Thita",
                "ce:initials": "T.",
                "ce:surname": "Chiasakul",
                "ce:indexed-name": "Chiasakul T."
            },
            "@seq": "1",
            "ce:initials": "T.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60022183",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183"
                },
                {
                    "@id": "60002746",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002746"
                }
            ],
            "ce:surname": "Chiasakul",
            "@auid": "56938997200",
            "author-url": "https://api.elsevier.com/content/author/author_id/56938997200",
            "ce:indexed-name": "Chiasakul T."
        },
        {
            "ce:given-name": "Rushad",
            "preferred-name": {
                "ce:given-name": "Rushad",
                "ce:initials": "R.",
                "ce:surname": "Patell",
                "ce:indexed-name": "Patell R."
            },
            "@seq": "2",
            "ce:initials": "R.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002746",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002746"
            },
            "ce:surname": "Patell",
            "@auid": "54682133800",
            "author-url": "https://api.elsevier.com/content/author/author_id/54682133800",
            "ce:indexed-name": "Patell R."
        },
        {
            "ce:given-name": "Anthony",
            "preferred-name": {
                "ce:given-name": "Anthony",
                "ce:initials": "A.",
                "ce:surname": "Maraveyas",
                "ce:indexed-name": "Maraveyas A."
            },
            "@seq": "3",
            "ce:initials": "A.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60107756",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60107756"
            },
            "ce:surname": "Maraveyas",
            "@auid": "6701792215",
            "author-url": "https://api.elsevier.com/content/author/author_id/6701792215",
            "ce:indexed-name": "Maraveyas A."
        },
        {
            "ce:given-name": "Marc",
            "preferred-name": {
                "ce:given-name": "Marc",
                "ce:initials": "M.",
                "ce:surname": "Carrier",
                "ce:indexed-name": "Carrier M."
            },
            "@seq": "4",
            "ce:initials": "M.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60107756",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60107756"
                },
                {
                    "@id": "60002173",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002173"
                }
            ],
            "ce:surname": "Carrier",
            "@auid": "57196834193",
            "author-url": "https://api.elsevier.com/content/author/author_id/57196834193",
            "ce:indexed-name": "Carrier M."
        },
        {
            "ce:given-name": "Jeffrey I.",
            "preferred-name": {
                "ce:given-name": "Jeffrey I.",
                "ce:initials": "J.I.",
                "ce:surname": "Zwicker",
                "ce:indexed-name": "Zwicker J.I."
            },
            "@seq": "5",
            "ce:initials": "J.I.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002746",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002746"
            },
            "ce:surname": "Zwicker",
            "@auid": "7003326377",
            "author-url": "https://api.elsevier.com/content/author/author_id/7003326377",
            "ce:indexed-name": "Zwicker J.I."
        }
    ]}
}}